These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21712496)

  • 41. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
    Bani-Sadr F; Goderel I; Morand P; Payan C; Lunel F; Pol S; Perronne C; Carrat F; Cacoub P
    AIDS; 2007 Jul; 21(12):1645-8. PubMed ID: 17630563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
    ;
    HIV Med; 2000 Mar; 1(2):76-101. PubMed ID: 11737331
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacogenetic considerations in the treatment of HIV.
    Mattevi VS; Tagliari CF
    Pharmacogenomics; 2017 Jan; 18(1):85-98. PubMed ID: 27976978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. UK HIV drug resistance database: background and recent outputs.
    Dunn D; Pillay D
    J HIV Ther; 2007 Dec; 12(4):97-8. PubMed ID: 18578092
    [No Abstract]   [Full Text] [Related]  

  • 45. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients.
    Hänsel A; Bucher HC; Nüesch R; Battegay M
    J Acquir Immune Defic Syndr; 2001 Feb; 26(2):191-3. PubMed ID: 11242189
    [No Abstract]   [Full Text] [Related]  

  • 46. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.
    Huisman MT; Smit JW; Schinkel AH
    AIDS; 2000 Feb; 14(3):237-42. PubMed ID: 10716499
    [No Abstract]   [Full Text] [Related]  

  • 47. Notes from the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2002.
    Susman E
    AIDS; 2003 Jan; 17(2):N1-2. PubMed ID: 12545099
    [No Abstract]   [Full Text] [Related]  

  • 48. [What is the optimal therapy?].
    Strehl E
    Med Monatsschr Pharm; 2014 Sep; 37(9):351-2. PubMed ID: 25282762
    [No Abstract]   [Full Text] [Related]  

  • 49. Psoriasis in an HIV-infected woman on antiretroviral therapy.
    Maitseo KN; Madan V; Tanko MN; Vento S
    Isr Med Assoc J; 2014 Apr; 16(4):262-3. PubMed ID: 24834768
    [No Abstract]   [Full Text] [Related]  

  • 50. Early treatment during primary infection holds the key to a functional cure for HIV.
    Lai Y
    Intervirology; 2014; 57(1):52-3. PubMed ID: 24157414
    [No Abstract]   [Full Text] [Related]  

  • 51. A novel method for determining the inhibitory potential of anti-HIV drugs.
    Shen L; Rabi SA; Siliciano RF
    Trends Pharmacol Sci; 2009 Dec; 30(12):610-6. PubMed ID: 19837466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progress in HIV-1 therapy continues on upward track.
    Montaner J; Mellors J
    Lancet; 1999 Feb; 353(9152):565. PubMed ID: 10028996
    [No Abstract]   [Full Text] [Related]  

  • 53. Limitations of current HIV therapies: opportunities for improvement.
    Powderly WG
    J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S7-12; quiz S13, 15-6. PubMed ID: 12946061
    [No Abstract]   [Full Text] [Related]  

  • 54. [HIV sleeping, sleeping...].
    Arm JY; Bonnet R; Gercekci C; Ndengera M; Wyssa BO; Cosson P; Soulié P
    Rev Med Suisse; 2015 Oct; 11(489):1863-4. PubMed ID: 26638518
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapy for persistent HIV.
    Keedy KS; Margolis DM
    Trends Pharmacol Sci; 2010 May; 31(5):206-11. PubMed ID: 20207023
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mouse viruses and human disease.
    Stewart AF; Cameron DW
    Lancet Infect Dis; 2011 Apr; 11(4):264-5. PubMed ID: 21453869
    [No Abstract]   [Full Text] [Related]  

  • 57. The pharmacogenomics of HIV therapy.
    Pirmohamed M; Back DJ
    Pharmacogenomics J; 2001; 1(4):243-53. PubMed ID: 11908767
    [No Abstract]   [Full Text] [Related]  

  • 58. [Retinal folds as a non-reported secondary effect of darunavir in a 20 year-old HIV patient].
    Hernández Bel L; Cabrera A; Domenech N; Moratal E Cervera B
    Arch Soc Esp Oftalmol; 2015 Sep; 90(9):451-3. PubMed ID: 25172528
    [No Abstract]   [Full Text] [Related]  

  • 59. The cancer-HIV/AIDS treatment conundrum.
    Schmidt C
    J Natl Cancer Inst; 2010 Nov; 102(21):1615-7. PubMed ID: 20966428
    [No Abstract]   [Full Text] [Related]  

  • 60. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls.
    Rodríguez-Barrios F; Gago F
    Curr Top Med Chem; 2004; 4(9):991-1007. PubMed ID: 15134553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.